Table 5. Cytotoxicity toward Pancreatic PSN-1 Cancer Cell Spheroids of Complexes 5–16 and Cisplatina.
| IC50 (μM) ± S.D. | |
|---|---|
| compound | PSN-1 |
| 5 [(PTA)2Cu(L1)][PF6] | 40.4 ± 2.0 |
| 6 [(PPh3)2Cu(L1)][PF6] | 8.3 ± 1.2 |
| 7 [(L1)CuCl2] | 33.0 ± 3.0 |
| 8 [(PTA)2Cu(L3)]PF6 | 11.6 ± 1.6 |
| 9 [(PPh3)2Cu(L3)]PF6 | 6.8 ± 0.4 |
| 10 [(L3)CuCl2] | 7.6 ± 0.3 |
| 11 [(PTA)2Cu(L2)][PF6] | 31.9 ± 4.0 |
| 12 [(PPh3)2Cu(L2)][PF6] | 22.0 ± 2.1 |
| 13 [(L2)CuCl2] | 34.0 ± 2.1 |
| 14 [(PTA)2Cu(L4)]PF6 | 6.6 ± 0.5 |
| 15 [(PPh3)2Cu(L4)]PF6 | 4.5 ± 0.4 |
| 16 [(L4)CuCl2] | 13.7 ± 3.7 |
| cisplatin | 52.6 ± 4.9 |
a
Cancer cell spheroids (2.5 × 103 cells/well) were treated for 72 h with the tested compounds. Cell viability was evaluated by means of the APH test. IC50 values were calculated from the dose–response curves obtained using the 4-PL logistic model (P < 0.05). S.D. = standard deviation.